Current Oncology Reports最新文献

Guidelines on Lifestyle Changes and Breast Cancer-where are we up to and how does this Apply to Black Women with Breast Cancer. 生活方式改变与乳腺癌的指导方针我们在做什么以及如何将其应用于患有乳腺癌的黑人妇女。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-28 DOI: 10.1007/s11912-025-01691-1

Sarah D Adomah, Susanne Cruickshank

{"title":"Guidelines on Lifestyle Changes and Breast Cancer-where are we up to and how does this Apply to Black Women with Breast Cancer.","authors":"Sarah D Adomah, Susanne Cruickshank","doi":"10.1007/s11912-025-01691-1","DOIUrl":"https://doi.org/10.1007/s11912-025-01691-1","url":null,"abstract":"Purpose of review: Breast cancer remains a significant health concern globally, with lifestyle factors playing a crucial role in its prevention and management. This paper aims to summarize the current lifestyle guidelines for breast cancer for consistency and consensus of best practice and to explore their specific implications for Black women with breast cancer.Recent findings: There has been a growing body of data from both observational studies and some randomised controlled trials showing the relationship between diet, physical activity, body weight and cancer risk and outcomes. These has led to established national and international guidelines emphasizing the importance of lifestyle advice for survivors in reducing breast cancer risk and a drive for healthcare professionals to guide practice. However, the application and impact of these guidelines can vary across different populations, including Black women, who face unique challenges and disparities in breast cancer outcomes. Breast cancer survivors can benefit from counselling about lifestyle changes across the continuum from diagnosis, treatment through to survivorship. Guidelines recommending these changes for breast cancer survivors have been developed to guide healthcare professionals for consistency and best practice. Culturally sensitive approaches and targeted strategies are crucial to effectively reduce breast cancer disparities and improve survival rates in this population.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hereditary Hematopoietic Malignancies: Considerations for Optimizing Diagnosis and Management. 遗传性造血恶性肿瘤：优化诊断和管理的考虑。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-26 DOI: 10.1007/s11912-025-01699-7

Amy M Trottier, Lea Cunningham, Lucy A Godley

引用次数: 0

Circulating Biomarkers in Sarcoma. 肉瘤中的循环生物标志物。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-17 DOI: 10.1007/s11912-025-01692-0

Taylor P Williams, Valerie P Grignol

引用次数: 0

Artificial Intelligence and Decision-Making in Oncology: A Review of Ethical, Legal, and Informed Consent Challenges. 肿瘤学中的人工智能和决策：伦理、法律和知情同意挑战的回顾。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-17 DOI: 10.1007/s11912-025-01698-8

Eliza-Maria Froicu, Ioana Creangă-Murariu, Vlad-Adrian Afrăsânie, Bogdan Gafton, Teodora Alexa-Stratulat, Lucian Miron, Diana Maria Pușcașu, Vladimir Poroch, Gema Bacoanu, Iulian Radu, Mihai-Vasile Marinca

{"title":"Artificial Intelligence and Decision-Making in Oncology: A Review of Ethical, Legal, and Informed Consent Challenges.","authors":"Eliza-Maria Froicu, Ioana Creangă-Murariu, Vlad-Adrian Afrăsânie, Bogdan Gafton, Teodora Alexa-Stratulat, Lucian Miron, Diana Maria Pușcașu, Vladimir Poroch, Gema Bacoanu, Iulian Radu, Mihai-Vasile Marinca","doi":"10.1007/s11912-025-01698-8","DOIUrl":"https://doi.org/10.1007/s11912-025-01698-8","url":null,"abstract":"Purpose of review: Artificial Intelligence (AI) integration in oncology is transforming therapeutic decision-making by providing clinical decision support. AI may improve treatment precision, but it raises ethical, legal, and informed consent issues. This review examines these paramount AI implementation issues in cancer care. This systematic review followed the PRISMA 2020 guidelines and was prospectively registered in the PROSPERO (CRD420251046482) database. A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane CENTRAL Library to identify studies published between January 2015 and May 2025. AI-supported oncology therapeutic decision-making studies with ethical, legal, or informed consent implications were eligible.Recent findings: Fifteen studies met the inclusion criteria. AI applications were found to support treatment recommendations, personalize drug dosing, and improve adherence and patient management. Despite these benefits, the review highlighted key concerns, including algorithmic transparency, unclear accountability in AI-guided decisions, data privacy, and gaps in patient understanding of AI's role in their care. AI has the potential to enhance oncological care, but ethical and legal issues must be addressed for safe and equitable implementation. Emphasis should be placed on developing robust informed consent models, mitigating algorithmic bias, and establishing clear legal accountability. Future research must establish ethical frameworks and regulatory mechanisms to protect patient autonomy and responsibly integrate AI into oncology.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining the Role of Postoperative Radio-Hormone Therapy in Prostate Cancer. 明确前列腺癌术后放射激素治疗的作用。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-13 DOI: 10.1007/s11912-025-01694-y

Harshitha Dudipala, Mai Dabbas, Kshitij Pandit, Sarika D Gurnani, Rana R McKay

{"title":"Defining the Role of Postoperative Radio-Hormone Therapy in Prostate Cancer.","authors":"Harshitha Dudipala, Mai Dabbas, Kshitij Pandit, Sarika D Gurnani, Rana R McKay","doi":"10.1007/s11912-025-01694-y","DOIUrl":"https://doi.org/10.1007/s11912-025-01694-y","url":null,"abstract":"Purpose of review: Postoperative radio-hormone therapy plays a significant role in management of prostate cancer after radical prostatectomy (RP), particularly in efforts to reduce biochemical recurrence (BCR), distant metastasis, and improve overall survival. BCR rates can be upwards of 50-70% at 5 years, highlighting the need for optimized risk stratification and consideration of multimodal treatment approaches. The purpose of this review is to highlight evidence-based treatment recommendations, and call attention to the importance of personalized therapeutic strategies after RP.Recent findings: Both radiotherapy (RT) and ADT have been shown to optimize survival outcomes and to reduce disease progression in patients with persistent PSA, pathologic lymph-node positive disease, and adverse pathology. Early salvage RT (SRT) is typically a preferred treatment approach as it allows for treatment intensification only when clinically indicated, avoiding unnecessary radiation in men who may never recur. ADT is often added to external beam radiation therapy (EBRT) to enhance treatment efficacy, particularly in patients with high-risk features, though in selected lower-risk scenarios, radiation alone may be sufficient. Short-term ADT is appropriate for low-intermediate risk patients and long-term is appropriate for patients with advanced pathological features or nodal involvement. For certain high-risk pathologic findings, such as positive surgical margins and seminal vesicle invasion (T3b), adjuvant RT (aRT) may be indicated to optimize disease control. Overall, radio-hormone therapy plays a significant role in the postoperative setting by reducing the risk of recurrence and disease progression, and improving survival outcomes. There are several well-validated tools that may offer personalized risk assessments to identify which patients may most benefit from adjuvant or salvage therapies. Finally, the optimal use of such therapies continues to be investigated with ongoing trials.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the Needs of Breast Cancer Survivors. 解决乳腺癌幸存者的需要。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-13 DOI: 10.1007/s11912-025-01687-x

Humaira Sarfraz, Fatima Tuz Zahra, Utsav Joshi, Tracey O'Connor

{"title":"Addressing the Needs of Breast Cancer Survivors.","authors":"Humaira Sarfraz, Fatima Tuz Zahra, Utsav Joshi, Tracey O'Connor","doi":"10.1007/s11912-025-01687-x","DOIUrl":"https://doi.org/10.1007/s11912-025-01687-x","url":null,"abstract":"Introduction: Breast cancer survivors experience unique treatment-related side effects that have long-standing and life-altering implications. These remain a challenging aspect both in terms of diagnosis and management for these patients.Objective: This article is a review of the latest key literature in the management of common side effects of treatment in breast cancer survivors namely infertility, vasomotor symptoms, sexual dysfunction, peripheral neuropathy, lymphedema, musculoskeletal symptoms, anthracycline-related cardiotoxicity, secondary malignancies, role of ctDNA, lifestyle modifications, strategies to maintain bone mineral density and addressing fear of cancer recurrence.Results: Recent research in the field has led to novel advancements for survivors planning a family, pharmacotherapeutic options for hot flashes, overcoming barriers such as adherence to therapy and management of long-term side effects, and a incorporating a multimodal approach to improve sexual health in women, neuropathy, musculoskeletal issues and lymphedema. There have been significant strides in the understanding and management of issues in breast cancer survivors. The increasing awareness and multimodal approach will continue to improve outcomes for survivors.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging Trends in Artificial Intelligence in Neuro-Oncology. 神经肿瘤学中人工智能的新趋势。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-12 DOI: 10.1007/s11912-025-01688-w

Saahil Chadha, Durga V Sritharan, Thomas Hager, Rahul D'Souza, Sanjay Aneja

引用次数: 0

Chronic Fatigue in Cancer Survivorship: Psychiatry Versus Oncology or Psychiatry with Oncology? 慢性疲劳在癌症幸存者中的作用：精神病学与肿瘤学或精神病学与肿瘤学？

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-11 DOI: 10.1007/s11912-025-01697-9

Vasilios Kafetzopoulos, Maria Pittaka, Georgios Ioannidis, Ivi Moniem

{"title":"Chronic Fatigue in Cancer Survivorship: Psychiatry Versus Oncology or Psychiatry with Oncology?","authors":"Vasilios Kafetzopoulos, Maria Pittaka, Georgios Ioannidis, Ivi Moniem","doi":"10.1007/s11912-025-01697-9","DOIUrl":"https://doi.org/10.1007/s11912-025-01697-9","url":null,"abstract":"Purpose of review: Cancer-related fatigue (CRF) is a prevalent and debilitating symptom among breast cancer survivors with a significant adverse impact on quality of life. This comprehensive review synthesizes the current understanding of CRF's complex pathophysiology, including the interplay of inflammatory, neuroendocrine, and psychosocial mechanisms, and evaluates diverse intervention strategies.Recent findings: Non-pharmacologic approaches (e.g., structured exercise, cognitive-behavioural therapy, mindfulness) have the strongest evidence for alleviating CRF and are emphasized as first-line treatments in oncology guidelines (e.g., ASCO, NCCN, ESMO). In contrast, pharmacologic options such as psychostimulants or bupropion show only modest benefits, with mixed efficacy and notable side effects, underscoring their limited role. Comparing oncology-focused guidelines with those for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) which are psychiatry-focused highlight key differences in management approaches and the need for a unified, multidisciplinary framework across specialties. Modern multidisciplinary, individualized survivorship care, integrating oncologic, psychosocial, and rehabilitative strategies call for adoption of updated, integrated clinical guidelines to optimally address CRF. By consolidating evidence and expert recommendations, this review aims to inform and enhance the clinical management of CRF and improve survivorship outcomes for breast cancer survivors.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Minimally Invasive Treatment Strategies for Metastatic Disease of the Skeleton: Current Concepts. 骨骼转移性疾病的微创治疗策略：当前概念。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-11 DOI: 10.1007/s11912-025-01696-w

Chloe Chose, Guston Zervoudakis, Thomas Karadimas, Thien Huong Huynh, Sean Lapp, Jonathan Henning, Ashley Lamba, David Joyce, Odion Binitie, Hakob Kocharyan, Vaiva Gustainyte, Mustafa Al-Roubaie, Alexander Lazarides

引用次数: 0

Retroperitoneal Sarcoma (RPS): A Systematic Review. 腹膜后肉瘤（RPS）：一项系统综述。

IF 4.7 2区医学

Current Oncology Reports Pub Date : 2025-06-04 DOI: 10.1007/s11912-025-01690-2

Ilaria Caturegli, Elizabeth J Lilley, Mark Fairweather, Jiping Wang, Chandrajit P Raut

引用次数: 0